{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:15:34Z","timestamp":1760044534295,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Czech Psychiatric Society"}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jpsychires.2015.08.013","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T12:39:11Z","timestamp":1439815151000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5729-3279","authenticated-orcid":false,"given":"Lenka","family":"P\u0159ibylov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kolek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0160\u00e1rka","family":"Vesel\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Duba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"\u0160lesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmila","family":"Dole\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpsychires.2015.08.013_bib1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/NDT.S4120","article-title":"Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature","volume":"4","author":"Abrams","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat. Dec"},{"issue":"5","key":"10.1016\/j.jpsychires.2015.08.013_bib2","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.09m05564yel","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder","volume":"71","author":"Canuso","year":"2010","journal-title":"J.\u00a0Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jpsychires.2015.08.013_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0b013e3181eeb600","article-title":"A\u00a0randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers","volume":"30","author":"Canuso","year":"2010","journal-title":"J.\u00a0Clin Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.08.013_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/NDT.S12612","article-title":"Role of paliperidone extended-release in treatment of schizoaffective disorder","volume":"6","author":"Canuso","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"year":"2014","author":"Experts","series-title":"Members of Czech Psychiatric Society: Doc. MUDr. Martin Anders PhD, Doc. MUDr. Jiri Masopust PhD, Doc. MUDr. Radovan Prikryl PhD, Doc. MUDr. Pavel Mohr PhD","key":"10.1016\/j.jpsychires.2015.08.013_bib5"},{"issue":"12","key":"10.1016\/j.jpsychires.2015.08.013_bib6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1176\/ps.46.12.1254","article-title":"Heavy utilization of inpatient and outpatient services in a public mental health service","volume":"46","author":"Kent","year":"1995","journal-title":"Psychiatr. Serv."},{"year":"2014","author":"Medicines","series-title":"State Institute for Drug Control: the List of Reimbursable Medicines 01\/10\/2014","key":"10.1016\/j.jpsychires.2015.08.013_bib7"},{"year":"2014","author":"Pinheiro","series-title":"Nlme: Linear and Nonlinear Mixed Effects Models","key":"10.1016\/j.jpsychires.2015.08.013_bib8"},{"year":"2014","author":"Procedures","series-title":"The List of Reimbursable Medical Procedures (Seznam Zdravotnich Vykonu S Bodovymi Hodnotami 2014)","key":"10.1016\/j.jpsychires.2015.08.013_bib9"},{"year":"2004","author":"R Core Team","series-title":"R: a Language and Environment for Statistical Computing","key":"10.1016\/j.jpsychires.2015.08.013_bib10"},{"year":"2013","author":"Siani","series-title":"Predictive Models for Utility from Positive and Negative Syndrome Scale Clinical Questionnaires for Schizophrenia in the United Kingdom, France and Germany \u2013 Findings for the European Schizophrenia Cohort (EuroSC)","key":"10.1016\/j.jpsychires.2015.08.013_bib11"},{"year":"2014","author":"SPC","series-title":"Summary of Product Characteristics \u2013 INVEGA","key":"10.1016\/j.jpsychires.2015.08.013_bib12"},{"year":"2014","author":"Walling","series-title":"XEPLION Study PRIME R092670-SCA-3004","key":"10.1016\/j.jpsychires.2015.08.013_bib13"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615002460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615002460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T02:01:33Z","timestamp":1537408893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395615002460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":13,"alternative-id":["S0022395615002460"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.08.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"type":"print","value":"0022-3956"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}